产品
编 号：F613896
分子式：C19H21ClN3NaO5S2
分子量：493.96
分子式：C19H21ClN3NaO5S2
分子量：493.96
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 261717-22-0
产品详情
生物活性：
Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia.
体内研究：
Clamikalant sodium (HMR 1098; 6.0 mg/kg; 5 min prior to EET administration) completely abolishes the cardioprotection produced by epoxyeicosatrienoic acid (EET).
体外研究：
Clamikalant sodium (HMR 1098; 40 μM) prevents improvement effect of Levosimendam on left ventricular developed pressure (LVDP) recovery rate, abolishes the inhibitory effect of Levosimendan on hypothermic preservation-induced activation of calpain, cleavage of Bid, and apoptosis.Clamikalant sodium (HMR 1098; 30 μM, 24 hours) reduces cellular viability, increases the apoptosis of Neonatal rat cardiomyocytes (NRCs) .Clamikalant sodium (30 μM) decreases the Bcl-2 protein level and increases the Bax protein level in the LPS-exposed NRCs.
Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia.
体内研究：
Clamikalant sodium (HMR 1098; 6.0 mg/kg; 5 min prior to EET administration) completely abolishes the cardioprotection produced by epoxyeicosatrienoic acid (EET).
体外研究：
Clamikalant sodium (HMR 1098; 40 μM) prevents improvement effect of Levosimendam on left ventricular developed pressure (LVDP) recovery rate, abolishes the inhibitory effect of Levosimendan on hypothermic preservation-induced activation of calpain, cleavage of Bid, and apoptosis.Clamikalant sodium (HMR 1098; 30 μM, 24 hours) reduces cellular viability, increases the apoptosis of Neonatal rat cardiomyocytes (NRCs) .Clamikalant sodium (30 μM) decreases the Bcl-2 protein level and increases the Bax protein level in the LPS-exposed NRCs.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备